Objective: We sought to determine the range and extent of neurologic complications due to pandemic influenza A (H1N1) 2009 infection (pH1N1Ј09) in children hospitalized with influenza.
there have been almost 18,449 deaths reported, although this is, without doubt, a gross underestimate. 3 Historically, pandemic influenza A (H1N1) virus infection has been associated with heightened neurologic complications and the 1918 H1N1 influenza pandemic may have been associated with encephalitis lethargica (EL), an atypical form of encephalitis. 4 Research on neurologic complications of 2009 pandemic influenza is important in order to support better diagnosis and treatment, advocate for prevention, and also to determine the degree of clinical similarity with the 1918 and 1976 H1N1 influenza viruses. 5 So far there have been few studies (mostly case reports and small series) on the neurologic complications associated with the 2009 pandemic influenza and comprehensive epidemiologic data on the neurologic complications of the 2009 pandemic influenza are lacking.
In this study we present prospectively collected surveillance data on the neurologic complications of pandemic influenza A (H1N1) 2009 from 6 major pediatric hospitals across Australia. The purpose of our study was to determine epidemiologic and clinical characteristics, including outcomes of neurologic complications, due to pandemic influenza A (H1N1) 2009 infection in children. We also compare this with published data on neurologic complications of pandemic influenza A (H1N1) 2009. Subsequently, ethics approval for this study was obtained from relevant Human Research Ethics Committees in each center. Informed consent was obtained from parents/carers of the participants prior to information being collected in each participating hospital. A diagnosis of encephalitis was made either clinically or pathologically (or both) as per standard definitions. 8 Encephalopathy was defined as altered level of consciousness for more than 24 hours, including lethargy, irritability, or change in personality and behavior. 9 Significant confusion or disorientation that did not fulfill criteria for encephalopathy was reported separately. Likewise, "loss of consciousness" that did not fulfill criteria for encephalopathy and was not associated with a seizure was reported separately. Clinical presentation of children with neurologic complications. Among children with neurologic complications, the most common presenting symptoms were fever (75.5%), cough (73.5%), seizure (63.2%), and coryza/runny nose (57.1%). Only 36.7% had the triad of cough, fever, and coryza/runny nose considered as influenza-like illness (ILI) on presentation, whereas 61.3% had 2 or more respiratory symptoms (e.g., cough, runny nose/coryza, sore throat, and dyspnea) and 38.7% had 1 or less (26.5% 1 and 12.2% none) respiratory symptoms. Demographic and clinical characteristics of the children with or without neurologic complications are presented in table 1.
Participants
Two-thirds of children with neurologic complications (n ϭ 31, 63.2%) presented with seizure and another 7 (14.3%) developed seizure following admission. Of those who had seizure (n ϭ 38), 23 had fever-associated seizure (predominantly generalized febrile convulsion, n ϭ 16) and 15 had afebrile seizure (12 with afebrile generalized tonic clonic seizure and 3 with afebrile focal seizure). Other neurologic complications included encephalitis/encephalopathy, confusion/disorientation, loss of consciousness, paralysis/GBS, and stroke (table 2) . Seven children (14.3%) with neurologic complications developed encephalitis/encephalopathy; 5 of them had preexisting health conditions. Of the 2 patients who were previously well, 1 developed pneumonia with empyema and had an asystolic arrest secondary to tension pneumothorax but survived with hypoxic encephalopathy. Another presented with a focal seizure and later developed generalized seizures and encephalopathy. Five (71.4%) of the 7 encephalitis/encephalopathy cases needed intensive care unit (ICU) admission, 1 of whom died (14.3%). All except 1 were aged at least 5 years. Five children with encephalitis/encephalopathy had a lumbar puncture. Influenza virus was not isolated from any sample. One had low CSF protein (0.13 g/L) and the rest did not have any CSF abnormalities. Clinical details of those children are given in table e-1 on the Neurology ® Web site at www.neurology.org.
Clinical course, treatment, and outcome. The median interval between onset of influenza symptoms (whether ILI or neurologic) and presentation to hospital was 1 day. Almost one-third (15 of 49) of children with neurologic complications needed ICU admission, the majority of which required mechanical ventilation (12 of 15) and 2 (4.1%) died. The mean length of stay (LOS) in hospital was 6.5 days (median 3 days, range 1-49 days) and mean LOS in ICU was 4.4 days (median 1.5 days, range 1-30 days). Four children (8.1%) had nosocomial influenza infection (initial hospital admission for another reason) and later developed neurologic complications.
We have calculated the odds of having neurologic complications among those with preexisting neurologic conditions admitted with influenza compared to the odds of having neurologic complications among those without preexisting neurologic conditions and admitted with influenza. Children with underlying neurologic conditions were 6.5 times more likely to have had neurologic complications from pandemic influenza A (H1N1) 2009 (95% CI 3.4 -12.4, p ϭ 0.0001). We have also compared neurologic complications in children with and without preexisting health conditions (table 2) . Mean LOS in hospital was shorter in those without preexisting health conditions ( p ϭ 0.008). Mean length of intensive care treatment also tended to be shorter in this group ( p ϭ 0.07). There were no differences between the 2 groups in types of neurologic complications, but the numbers were too small to make reliable comparisons for each complication.
About three-fifths (61.2%) of the children with neurologic complications were treated with oseltamivir phosphate (Tamiflu, Roche Products Pty Ltd., Dee Why, NSW, Australia) during admission. There was no relationship between use of oseltamivir phosphate and development of seizures (RR 1, 95% CI 0.5-1.8, p ϭ 0.65), any neurologic complications (p ϭ 0.62), or death (p ϭ 0.51) but numbers were small. Just over half of the children (55.1%) with neurologic complications were treated with antibiotics and 16.3% had laboratory proven bacterial coinfection. Two children died from neurologic complications of pandemic influenza; both had preexisting health conditions. 10 -32 Unlike our series, most reports were focused only on more severe complications such as encephalitis. The median age of these published cases was 7 years (range 0.25-17 years), with 61.6% male. The most common neurologic complications identified were seizure (30, 34.5%), encephalopathy (25, 28.7%), Abbreviations: GBS ϭ Guillain-Barré syndrome; ICU ϭ intensive care unit; LOS ϭ length of stay.
encephalitis (9, 10.3%), seizure with encephalopathy (8, 9.2%), and acute necrotizing encephalitis (5, 5.7%). We were able to calculate the proportion of neurologic complications in children hospitalized with laboratory-confirmed pandemic influenza in 2009 from 3 studies, 2 in the United States (5.9% and 7.5%) and 1 in the United Kingdom (6.0%). 15, 19, 29 The proportion of encephalopathy in children hospitalized with laboratory-confirmed pandemic influenza was 1.7% in another study. 12 The presenting symptoms, neurologic complications, CSF and neuroimaging findings, treatment, and outcome of the 87 children are summarized in table e-2.
DISCUSSION This is one of the largest prospective cohorts (n ϭ 49) of pediatric neurologic complications associated with pandemic influenza to be presented in a single study generated from a large-scale collaboration between researchers from 6 major pediatric hospitals in 4 different states in Australia.
In our study, we found that neurologic complications (9.7%) were quite frequently reported among children hospitalized with 2009 pandemic influenza. A retrospective cohort study from the United States found that 8.5% of laboratory-confirmed seasonal influenza hospitalized cases had neurologic complications.
1 Another recent retrospective study comparing seasonal and pandemic influenza found 5.9% of 303 laboratory-confirmed hospitalized pandemic influenza cases had neurologic complications compared with 6.8% in seasonal influenza cases. However, the authors stated that compared to seasonal influenza, patients with pandemic 2009 influenza were more likely to have encephalopathy, focal neurologic findings, aphasia, and abnormal electroencephalographic findings. 15 Another study from Australia in 2007 (of influenza hospitalization in one of our surveillance hospitals) found 1.6% (2 of 122) of hospitalized children with laboratory-confirmed seasonal influenza had encephalitis. 33 Our findings, from influenza surveillance and literature review, suggest that the proportion of neurologic complications associated with the 2009 pandemic influenza admissions is comparable to that from published studies of seasonal influenza complications. They also highlight that both seasonal and pandemic influenza are associated with a significant burden of neurologic complications.
Half the children who developed neurologic complications were younger than 5 years and more than half had preexisting medical conditions. There were 2 fatal cases (4.1%) in this study, both with preexisting health conditions. Our observations are consistent with the previous finding from the United States that children with chronic medical conditions (mostly neurodevelopmental conditions) are at increased risk of severe complications of influenza and death. 34, 35 Moreover, our study shows that children admitted with influenza to hospital who had underlying neurologic conditions are particularly more likely to have neurologic complications from influenza. Through our literature review, we have identified another 7 fatal cases from neurologic complications of pandemic influenza. Encephalitis/encephalopathy was also a relatively common complication of pandemic influenza. Of the 7 encephalitis/encephalopathy cases in our study, 1 died. However, among the survivors all but 1 (i.e., 5 of 6) appeared to recover without obvious sequelae. The long-term outcome of this group is poorly understood and it is important to follow up survivors of neurologic complications from influenza.
In our study, the diagnosis of influenza was not considered until late in some children presenting with neurologic complications (e.g., stroke), probably because respiratory symptoms were atypical or absent. Over 60% did not have the triad of cough, coryza/runny nose, and fever and 12.2% had no respiratory symptoms. It is important that clinicians consider the diagnosis of influenza in children presenting with neurologic symptoms during seasonal epidemics or pandemics of influenza.
An apparent disproportionately high number of children with neurologic complications during the 2009 pandemic were from ethnic minorities (table  1) . Our finding is also consistent with the findings from the United Kingdom and United States that ethnic minority groups were disproportionately affected by severe illness. 36 In our study, only 14.8% of children with preexisting health conditions had received seasonal influenza vaccine in 2009. This low influenza vaccine uptake among high-risk groups occurred even though vaccination is recommended and government funded in Australia for those with predisposing medical conditions. Despite widespread fear early in the 2009 pandemic, when pandemic vaccine became available, its uptake was low in Australian children (aged Ͻ15 years); by February 2010 only 6.8%. 37 There is no specific treatment for influenza neurologic complications. Our data inform a better understanding of the clinical and epidemiologic characteristics of neurologic complications of influenza in children, and add to the evidence to support universal influenza vaccination of children.
There has been some recent concern regarding the use of oseltamivir phosphate and neurologic side effects in children. 38 In our cohort 61.2% of the children were treated with oseltamivir phosphate after admission. However, within the constraints of small numbers, there was no relationship between use of oseltamivir phosphate and development of seizures
was terminated because of a suspected neurologic complication (GBS) associated with the influenza vaccine. 39 Interestingly, in our cohort we found 2 previously healthy children who developed paralysis/GBS as a complication of pandemic influenza. All forms of GBS are probably due to an immune response to foreign antigens and in this case probably to the highly immunogenic pandemic virus infection. Recent pandemic (H1N1) 2009 vaccine studies have shown that the 2009 hemagglutinin antigen is so immunogenic that even a single and small dose of unadjuvanted vaccine is sufficient to produce an impressive immune response. 40 The pathophysiology of influenza-associated encephalopathy is poorly understood and may involve viral invasion of the CNS, proinflammatory cytokines, metabolic disorders, or genetic susceptibility. In our study, absence of CSF pleocytosis and detectable virus by PCR/culture in the CSF supports an immune-mediated or autoimmune mechanism of influenza-associated encephalopathy, as opposed to direct viral invasion of the CNS.
Our study has some limitations. We have only included admissions to major children's hospitals and not to district general hospitals and thus severe neurologic complications may well have been overrepresented. We have only reported laboratoryconfirmed cases of pandemic influenza. Later in the pandemic some of the surveillance hospitals did not do routine influenza diagnostic tests due to the overwhelming workload associated with the unprecedented influx of admissions, and thus the number of reported cases was possibly lower than the actual number for those hospitals. We have not performed detailed follow-up of surviving patients to detect potential long-term sequelae.
Our study suggests that neurologic complications of influenza are common and can be potentially lifethreatening. Children with preexisting conditions as well as healthy children are at risk of influenza neurologic complications. The rate of influenza vaccination, even among those with high-risk conditions, is very low in children in this study. The specific treatment for influenza-related neurologic complications is uncertain, underlining the importance of early diagnosis, use of antivirals, and the potential for universal influenza vaccination in children. The burden and long-term outcome of neurologic complications associated with influenza need further attention.
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1
Khandaker and colleagues 2 provide a useful perspective regarding the neurologic disease burden associated with H1N1 influenza infection in children. Their report emphasizes that children with preexisting neurologic conditions, such as cerebral palsy, developmental delay, epilepsy, and others, were especially vulnerable to the potential neurologic morbidity of H1N1 infection. More than 50% of the children with neurologic complications of H1N1 infection described in this report had preexisting neurologic conditions. This phenomenon, while extremely important from a clinical perspective, is not unique to H1N1 influenza infection; increased neurologic disease burden or increased mortality rates among children with underlying neurodevelopmental disorders have been observed during infections with other viruses, including seasonal influenza. 
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